Plasma vascular endothelial growth factor and angiogenin are positively related to erythropoietin dose in hemodialysis patients

• Published in: Advances in medical sciences Vol. 58; no. 1; pp. 143 - 149
• Main Authors: Eleftheriadis, T, Antoniadi, G, Liakopoulos, V, Pissas, G, Galaktidou, G, Stefanidis, I
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Urban & Partner Sp. z o.o 2013; Elsevier Limited
• Subjects: Aged; angiogenin; Diabetes Complications - blood; diabetes mellitus; Dose-Response Relationship, Drug; erythropoietin; Erythropoietin - therapeutic use; Female; Gene Expression Regulation; hemodialysis; hemoglobin; Humans; Inflammation; Interleukin-6 - blood; Kidney Failure, Chronic - blood; Kidney Failure, Chronic - metabolism; Kidney Failure, Chronic - therapy; Male; Middle Aged; Renal Dialysis; Ribonuclease, Pancreatic - blood; Tumor Necrosis Factor-alpha - blood; vascular endothelial growth factor; Vascular Endothelial Growth Factor A - blood; angiogenin; inflammation; vascular endothelial growth factor; hemodialysis; diabetes mellitus; hemoglobin; erythropoietin
• ISSN: 1896-1126; 1898-4002
• DOI: 10.2478/v10039-012-0071-1

Experimental data confirmed that erythropoietin (EPO) administration alters the course of various pathological situations such as heart failure and tumor growth by inducing vascular endothelial growth factor-A (VEGF-A) expression. The effect of EPO dose on plasma VEGF-A level in hemodialysis (HD) patients was evaluated. The effect of EPO dose on plasma angiogenin level in HD patients was also evaluated, since angiogenin is necessary for angiogenesis induced by VEGF-A. Thirty two HD patients (10 diabetics) enrolled into the study. Patients were iron replete and did not suffer from infections, autoimmune diseases or malignancies. Plasma VEGF-A and angiogenin, as well as serum interleukin-6 and tumor necrosis factor-α were measured by means of ELISA. Weekly EPO dose per kg of dry body weight was positively related to both VEGF-A and angiogenin, whereas no relation was detected among VEGF-A or angiogenin and hemoglobin, inflammation or presence of diabetes mellitus. These relations among EPO dose and VEGF-A or angiogenin remained after adjustment for hemoglobin concentration or inflammation or presence of diabetes mellitus. EPO dose may affect plasma VEGF-A and angiogenin concentrations in HD patients.